Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

25 mg film - coated tablets

Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

50 mg film - coated tablets

Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

100 mg film - coated tablets

Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

50 mg/850 mg film - coattd tablets

Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

51 mg/1000 mg film - coattd tablets

Bulgaristan - Bulgarca - БАБХ (Българска агенция по безопасност на храните)

boehringer ingelheim vetmedica gmbh - lowsonia intracellularis, жива аттенуированная - лиофилизат и разтворител за перорална суспензия - min. 10 на степен 4, 9 - max. 10 на степен 6, 1 tcid 50 - свине

Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

novartis pharma gmbh - Кальцитонин (сьомга синтетични) - 100 iu/ml solution for injection

Bulgaristan - Bulgarca - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v. - жив атенуиран сальмонеллу, чревната пръчка подтип enterica салмонелл, серовар enteritidis, не, щам cal10 см+/Риф+/ssq- - лиофилизат за прилагане с вода за пиене - 1-6 x 10 на степен 8 cfu - пилета

Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - Имунологични средства за суици - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Друг ключов фактор, допринасящ за разяждането на глиган, skatole, също може да бъде намален като косвен ефект. Агресивното и сексуално (монтажно) поведение също се намалява. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant може да се използва като монотерапия или в комбинация с метотрексат. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.